Prevalence of Hepatitis c Virus Infection Among Rheumatological Patients

Sponsor

Assiut University (Other)

Overall Status

Completed

CT.gov ID

NCT03587714

Collaborator

(none)

800

Enrollment

Location

13.9

Actual Duration (Months)

57.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Egypt has the highest prevalence of hepatitis C virus (HCV) in the world. In 2015, the prevalence of HCV RNA was found to be 7.0%.(1) The prevalence of HCV was studied in Rheumatoid arthritis in few studies(2,3), but to our knowledge, no previous work studied it in other rheumatologic diseases.

Condition or Disease	Intervention/Treatment	Phase
Hepatitis C	Diagnostic Test: HCV RT-PCR

Detailed Description

This study aims at detecting the prevalence of subclinical HCV infection in different rheumatologic disease groups in Egypt.

Consecutive patients with different rheumatologic diseases from seven- geographically different- rheumatology departments were prospectively studied. None of the patients was known to have previous HCV infection. Patients' serum samples were screened for the presence of anti-HCV antibodies. Patients with positive serology were further evaluated for the presence of HCV ribonucleic acid by reverse transcriptase polymerase chain reaction (RT-PCR)

Study Design

Study Type:

Observational [Patient Registry]

Actual Enrollment :

800 participants

Observational Model:

Cohort

Time Perspective:

Cross-Sectional

Official Title:

Prevalence of Hepatitis c Virus Infection Among Rheumatological Patients

Actual Study Start Date :

Jan 1, 2017

Actual Primary Completion Date :

Dec 1, 2017

Actual Study Completion Date :

Mar 1, 2018

Outcome Measures

Primary Outcome Measures

HCV RT-PCR [3 months]
positive

Eligibility Criteria

Criteria

Ages Eligible for Study:

20 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Consecutive patients with different rheumatologic diseases from seven- geographically different- rheumatology departments were prospectively studied. None of the patients was known to have previous HCV infection

Exclusion Criteria:

pregnancy and end organ failure

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Assiut governorate	Assiut		Egypt

Sponsors and Collaborators

Assiut University

Investigators

Principal Investigator: Manal Hassanien, MD, Assiut University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Manal Hassanien, principle investigaror, Assiut University

ClinicalTrials.gov Identifier:

NCT03587714

Other Study ID Numbers:

Hepatitis C

First Posted:

Jul 16, 2018

Last Update Posted:

Jul 16, 2018

Last Verified:

Jul 1, 2018

Individual Participant Data (IPD) Sharing Statement:

Yes

Plan to Share IPD:

Yes

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 16, 2018